Pediatric Hematology

📚 02 Pediatric Superspecialities • 🎯 186 High-Yield MCQs • Nelson 22nd Edition Standard

Granulopoiesis & Hematopoietic Transcription Factors

  • Neutrophil Lineage Commitment: ((PHEM001)): Granulocytic differentiation from common myeloid progenitors to neutrophils is driven by the transcription factor C/EBPα (with G-CSF acting as the lineage-specific growth factor). - Distractors: GATA1 directs erythroid, megakaryocytic, eosinophilic, and basophilic lineages. GATA3 is involved in T-cell development. PU.1 regulates broader myeloid/monocytic differentiation.

Embryonic & Fetal Hemoglobin Switching

  • Embryonic Hemoglobin Composition: ((PHEM002)): Hemoglobin Gower-1 is composed of two ζ-globin chains (chromosome 16) and two ε-globin chains (chromosome 11) ($\zeta_2\varepsilon_2$). - Distractors: Gower-2 = $\alpha_2\varepsilon_2$; Portland = $\zeta_2\gamma_2$; HbF = $\alpha_2\gamma_2$.
  • Postnatal HbF Decline & Prematurity: ((PHEM003)): In premature infants, the fall in fetal hemoglobin (HbF) follows postconceptional age more closely than chronological postnatal age, leading to prolonged persistence of higher HbF levels compared to term infants.
  • γ-Globin Silencing & Fetal-to-Adult Switch: ((PHEM004)): The transcription factor BCL11A binds near the $\beta$-globin gene cluster and directly silences $\gamma$-globin expression during the fetal-to-adult hemoglobin switch. - Distractors: GATA1 regulates erythroid differentiation but does not mediate $\gamma$-globin silencing.

Congenital & Acquired Red Cell Disorders

  • Diamond-Blackfan Anemia (DBA) Criteria: ((PHEM005)): Diagnosis requires age $<1$ year, macrocytic anemia without cytopenias, reticulocytopenia, and normal marrow cellularity with a paucity of erythroid precursors. - Major Supporting Criteria: Pathogenic variant described in classical DBA. - Minor Supporting Criteria: Elevated red cell adenosine deaminase (eADA), classical congenital anomalies, and elevated HbF.
  • Parvovirus B19 Aplastic Crisis: ((PHEM006)): Parvovirus B19 infects erythroid precursors, causing transient red cell aplasia in chronic hemolytic states (e.g., hereditary spherocytosis, sickle cell disease). Marrow findings reveal giant pronormoblasts with intranuclear inclusions and severe reticulocytopenia. - Distractors: Ringed sideroblasts with vacuolated precursors indicate Pearson syndrome.
  • Anemia of Chronic Disease / Inflammation: ((PHEM007)): Inflammatory cytokines (e.g., IL-6) increase hepatic hepcidin production, which binds to ferroportin on enterocytes and macrophages, triggering its internalization and lysosomal degradation. This traps iron and lowers serum iron despite normal/high ferritin.
  • Anemia of Prematurity: ((PHEM008)): Preterm infants develop severe anemia by 3-6 weeks with inappropriately low EPO because the developmental switch from hepatic to renal EPO production is delayed, and the hepatic oxygen sensor is less responsive to hypoxia than the renal sensor.
  • Folate vs. Vitamin B12 Depletion Kinetics: ((PHEM009)): On a folate-free diet, megaloblastic anemia develops rapidly within 2–3 months due to limited body stores (unlike vitamin B12 stores, which take years to deplete).
  • Parasitic Vitamin B12 Deficiency: ((PHEM010)): Diphyllobothrium latum (fish tapeworm, acquired via undercooked freshwater fish) causes vitamin B12 deficiency and megaloblastic anemia despite normal gastric intrinsic factor.
  • Biomarkers of Vitamin B12 Deficiency: ((PHEM011)): Increased methylmalonic acid (MMA) and increased homocysteine are seen in B12 deficiency, but elevated MMA is highly specific for vitamin B12 deficiency (whereas homocysteine also rises in folate deficiency and renal failure).
  • Hereditary Spherocytosis (HS) Screening: ((PHEM012)): Eosin-5-maleimide (EMA) binding test via flow cytometry demonstrates decreased EMA binding to band 3 and related membrane proteins, providing superior sensitivity/specificity compared to osmotic fragility.
  • Southeast Asian Ovalocytosis (SAO): ((PHEM013)): Caused by a mutant band 3 protein producing a rigid erythrocyte membrane and ovalocytes with a characteristic transverse bar. Presents transiently in neonates and provides natural protection against cerebral malaria.
  • Echinocyte (Burr Cell) Associations: ((PHEM014)): Echinocytes feature regularly distributed surface projections and occur non-artifactually in pyruvate kinase deficiency, uremia/end-stage renal disease, and liver disease. - Distractors: Acanthocytes (spur cells with irregular projections) are seen in abetalipoproteinemia and chorea-acanthocytosis.
  • Sickle Cell Trait (AS) Complications: ((PHEM015)): Though generally benign, sickle cell trait is classically associated with renal papillary necrosis (due to extreme hypoxia/acidosis in the renal medulla promoting sickling), hematuria, and hyposthenuria.
  • $\alpha$-Thalassemia Genotypes & Hb Bart's: ((PHEM016)): Hemoglobin H disease results from a three $\alpha$-globin gene deletion, characterized by microcytic hypochromic anemia, hepatosplenomegaly, and 20–30% Hb Bart's on newborn screening without regular transfusion dependence.
  • Non-Transfusion-Dependent Thalassemia (Thalassemia Intermedia): ((PHEM017)): Characterized by ineffective erythropoiesis that suppresses hepcidin production, leading to increased gastrointestinal iron absorption and significant iron overload even without frequent transfusions.
  • Warm Autoimmune Hemolytic Anemia (WAIHA): ((PHEM018)): Mediated predominantly by IgG autoantibodies active at 37°C, resulting in erythrocyte coating and extravascular destruction by splenic macrophages, classically yielding spherocytes and a strongly positive DAT. - Distractors: Cold agglutinin disease involves IgM and complement fixation with intravascular hemolysis.
  • Paroxysmal Cold Hemoglobinuria (PCH): ((PHEM019)): Mediated by the Donath-Landsteiner hemolysin (IgG anti-P autoantibody), which binds RBCs in cold temperatures and fixes complement to cause intravascular hemolysis upon rewarming to 37°C, often following viral infections.
  • Drug-Induced Immune Hemolytic Anemia (Ternary Immune Complex Mechanism): ((PHEM020)): Drugs (e.g., cephalosporins, quinidine) can induce immune complexes that bind RBCs, producing a positive DAT with anti-C3 and predominantly intravascular hemolysis. - Distractors: Hapten-mediated/drug adsorption (e.g., penicillin) shows positive anti-IgG and extravascular hemolysis.

Thrombosis, Hemostasis & Coagulation

  • Antiphospholipid Syndrome (APS) Diagnosis: ((PHEM021)): Definite APS requires at least one clinical criterion (thrombosis or pregnancy morbidity) and persistent laboratory positivity for lupus anticoagulant, anticardiolipin, or anti-$\beta_2$GPI antibodies on two or more occasions at least 12 weeks apart. A single positive test is often transient.
  • Warfarin Embryopathy: ((PHEM022)): First-trimester warfarin exposure causes chondrodysplasia punctata, characterized by nasal hypoplasia and radiological stippled epiphyseal and vertebral calcifications.
  • Inherited Platelet Disorders & Platelet Size: ((PHEM023)): - Large Platelets: Bernard-Soulier syndrome (GPIb-IX-V defect), platelet-type vWD, and 22q11.2 deletion (GP1BB). - Normal Platelet Size / Storage Pool Defect: Hermansky-Pudlak syndrome ($\delta$-granule deficiency with oculocutaneous albinism) does not feature large platelets.
  • Neonatal Alloimmune Thrombocytopenia (NAIT): ((PHEM024)): Caused by maternal IgG alloantibodies directed against paternal platelet antigens (most commonly HPA-1a) inherited by the fetus. The mother's own platelet count is normal.
  • Splenic Hypofunction Quantification: ((PHEM025)): Detection of pitted erythrocytes by phase-interference microscopy allows precise quantification of splenic filtering function over a wide range, correlating closely with radionuclide scans.
  • Inherited Bone Marrow Failure Syndromes: ((PHEM026)): Fanconi anemia is the most common inherited bone marrow failure syndrome (autosomal recessive DNA repair defect with radial/thumb anomalies and pancytopenia).
  • Acquired Aplastic Anemia Epidemiology: ((PHEM027)): Idiopathic / immune-mediated T-cell destruction accounts for $\approx 70\text{–}80\%$ of pediatric aplastic anemia cases globally.
  • Primary Immunodeficiency Epidemiology: ((PHEM028)): Selective IgA Deficiency is the most common primary immunodeficiency worldwide (prevalence 1:300 to 1:3000).
  • Thrombotic Thrombocytopenic Purpura (TTP) Pathophysiology: ((PHEM029)): Caused by autoantibody-mediated deficiency of ADAMTS13 (a metalloprotease), leading to failure to cleave ultra-large von Willebrand factor multimers, subsequent microvascular thrombosis, microangiopathic hemolytic anemia, and thrombocytopenia.
  • Nutritional Anemias & Iron Bioavailability: ((PHEM030)):
  • Iron deficiency: is the most common nutritional cause of anemia globally, characterized biochemically by low serum ferritin and high total iron-binding capacity (TIBC). - Heme iron (found in animal sources like chicken liver and red meat) offers the most bioavailable dietary iron absorption compared to plant-derived non-heme iron.
  • Vitamin B12 Deficiency Neuropathy: ((PHEM032)): Cobalamin deficiency causes demyelination of the posterior (dorsal) columns and lateral corticospinal tracts, manifesting as subacute combined degeneration of the spinal cord.
  • Hemophilia A Laboratory Profile: ((PHEM034)): Factor VIII deficiency presents with normal bleeding time, normal PT, and prolonged aPTT.
  • Inherited Coagulation Disorder Epidemiology: ((PHEM035)): von Willebrand disease (vWD) is the most common inherited bleeding disorder worldwide (prevalence up to 1%), far outstripping hemophilia A.

Hemoglobinopathies & Thalassemias

  • β-Thalassemia Major Molecular Defects: ((PHEM036)): In India, the most common mutation is the IVS 1-5 (G→C) point mutation in intron 1 of the $\beta$-globin gene, accounting for 30–50% of alleles and causing a $\beta^0$-thalassemia phenotype via aberrant mRNA splicing.
  • Thalassemia-Induced Osteoporosis Diagnostic Criteria: ((PHEM037)): Defined by a BMD Z-score $\le$ -2.0 AND a history of clinically significant fractures ($\ge$ 2 long bone fractures before age 10 years, or $\ge$ 3 long bone fractures up to age 19 years) in the absence of trauma.
  • Sickle Cell Disease (SCD) Pathophysiology & Novel Therapeutics: ((((PHEM038)) · ((PHEM040)))): The primary mutation is a Valine substitution for Glutamic acid at position 6 (Glu$\to$Val) of the $\beta$-chain. Voxelotor acts as a hemoglobin S polymerization inhibitor that allosterically increases the oxygen affinity of HbS to reduce hemolysis.
  • Sickle Cell Trait (HbAS) Complications: ((((PHEM040)) · ((PHEM039)))): Usually asymptomatic, but extreme physiological stress (hypoxia, dehydration, high altitude) can precipitate acute splenic infarction. Note: HbAS does not cause stroke, aplastic crises, or vaso-occlusive pain crises.
  • Modifiers of Sickle Cell Phenotype: ((PHEM040)): Milder phenotype and higher HbF are promoted by BCL11A silencing (repressor of $\gamma$-globin), $\gamma\delta\beta$-globin gene deletions (HPFH), and the XmnI polymorphism in the $\gamma$-globin promoter.
  • Acute Splenic Sequestration Crisis: ((PHEM041)): Life-threatening emergency in HbSS presenting with rapid Hb drop, massive splenomegaly, and hypovolemic shock. Managed by careful transfusion of PRBCs to a target Hb of ~8 g/dL; avoid rapid over-transfusion (target 10–12 g/dL) to prevent hyperviscosity and stroke. Splenectomy is reserved for recurrent episodes.
  • Homozygous $\delta\beta$-Thalassemia vs. $\beta$-Thalassemia: ((((PHEM063)) · ((PHEM064)))): Homozygous $\delta\beta$-thalassemia presents with 0% HbA, nearly complete replacement by HbF (high HbF), and low/normal HbA₂ due to simultaneous $\delta$ and $\beta$ gene deletions. Compound heterozygous $\delta\beta$-thalassemia/$\beta$-thalassemia presents as a transfusion-dependent thalassemia major phenotype.
  • Transfusion Targets & Complications in Thalassemia: ((PHEM066)): Maintain pre-transfusion Hb at 9–10.5 g/dL using extended RBC phenotyping (ABO, Rh, Kell) to prevent alloimmunization. Symptomatic hypersplenism (early satiety, pancytopenia, increased transfusion requirement) warrants splenectomy.
  • Iron Chelation Management & Monitoring: ((((PHEM067)) · ((PHEM068)) · ((PHEM070)))): - Persistent hyperferritinemia on deferasirox requires stepwise dose escalation by 10 mg/kg/day every 2 months (up to 40 mg/kg/day). - Isolated hepatic iron overload (normal cardiac T2*) is well managed with deferasirox monotherapy ((PHEM070)). - Severe cardiac iron overload (CMR T2* < 10 ms) requires intensive combination chelation with deferiprone + deferoxamine. - Deferasirox toxicity includes proximal renal tubular dysfunction (Fanconi syndrome: normoglycemic glycosuria, phosphaturia, alkaline urine).

Red Cell Enzymopathies & Membrane Disorders

  • Hereditary Spherocytosis (HS) Masking Factors: ((PHEM042)): Conditions that obscure HS hemolysis or laboratory findings include nutritional anemia, iron deficiency, and cholestasis. HbAS (sickle cell trait) does not mask HS.
  • Pyruvate Kinase (PK) Deficiency Pathophysiology: ((PHEM043)): Defective glycolysis leads to insufficient ATP production, causing failure of the Na$^+$/K$^{+}$-ATPase pump, cellular dehydration, echinocyte formation, and premature extravascular hemolysis. (Distinguish from G6PD deficiency which causes oxidative stress via insufficient NADPH, and MetHb reductase deficiency which causes methemoglobinemia).
  • Paroxysmal Cold Hemoglobinuria (PCH): ((PHEM061)): Post-viral acute intravascular hemolysis mediated by the biphasic Donath-Landsteiner autoantibody (complement-fixing IgG). The critical transfusion rule is to use an in-line blood warmer at 37°C to prevent donor RBC lysis.
  • Autoimmune Hemolytic Anemia (AIHA) Management: ((PHEM062)): For steroid-refractory warm AIHA, the preferred second-line therapy is rituximab (anti-CD20 monoclonal antibody).

Nutritional & Bone Marrow Failure Syndromes

  • Iron Deficiency vs. Megaloblastic Anemia: ((((PHEM051)) · ((P1HEM052)) · ((PHEM053)) · ((PHEM054)) · ((PHEM055)))):
  • Iron Deficiency:: Microcytic hypochromic anemia with very low ferritin (<12 ng/g). Earliest response to oral iron is reticulocytosis at 5–7 days. When ferritin is normal/falsely elevated by inflammation, soluble transferrin receptor (sTfR) differentiates iron deficiency from anemia of chronic disease.
  • Vitamin B12 Deficiency:: Macrocytic anemia (high MCV) with glossitis, paresthesias, and hypersegmented neutrophils, common in vegetarians.
  • Folate Deficiency:: Megaloblastic anemia with macro-ovalocytes and hypersegmented neutrophils, classically seen in celiac disease due to proximal small bowel malabsorption.
  • Inherited Bone Marrow Failure Syndromes: ((((PHEM045)) · ((PHEM046)) · ((PHEM047)))):
  • Fanconi Anemia:: Pancytopenia + hypocellular marrow + congenital anomalies (short stature, café-au-lait spots, hypoplastic thumbs/radial defects). Diagnosed via chromosomal breakage studies.
  • Dyskeratosis Congenita:: Telomere biology disorder characterized by the mucocutaneous triad (nail dystrophy, oral leukoplakia, reticular skin pigmentation) and pancytopenia. Diagnosed via shortened telomere length.
  • Acquired Aplastic Anemia:: Pancytopenia + hypocellular marrow (<20%) without congenital malformations.
  • Parvovirus B19 in Immunocompromised Hosts: ((PHEM069)): Causes chronic pure red cell aplasia (PRCA) with severe anemia and reticulocytopenia due to persistent infection of erythroid precursors.

Bleeding Disorders & Thrombotic Microangiopathies

  • Platelet Function Disorders: ((PHEM044)): Glanzmann thrombasthenia (GPIIb/IIIa deficiency / integrin $\alpha$IIb$\beta$3) presents with normal platelet count, prolonged bleeding time, absent aggregation with ADP, collagen, and epinephrine, but normal aggregation with ristocetin, and reduced CD41/CD61 expression on flow cytometry.
  • Hemophilia A & Inhibitor Development: ((((PHEM056)) · ((PHEM057)) · ((P1HEM058)) · ((PHEM060)))): - X-linked inheritance, deep tissue bleeding/hemarthroses, prolonged aPTT with normal PT. - Mixing studies correct aPTT in factor deficiency, but fail to correct when factor VIII inhibitors (neutralizing alloantibodies) develop. - Bleeding episodes with high-titer inhibitors require bypassing agents (aPCC or recombinant factor VIIa), not factor VIII concentrate.
  • von Willebrand Disease (vWD): ((PHEM059)): Characterized by mucocutaneous bleeding (gum bleeding, epistaxis), prolonged bleeding time, and variably prolonged aPTT with normal PT.
  • Thrombotic Microangiopathies (TTP vs. HUS): ((PHEM050)): TTP presents with the classic pentad: fever, neurological symptoms, thrombocytopenia, microangiopathic hemolytic anemia (schistocytes, high LDH), and renal dysfunction, caused by ADAMTS13 deficiency. (Contrast with HUS, which typically follows Shiga toxin-producing E. coli diarrhea in younger children with prominent renal failure and minimal neurology).

Primary Immunodeficiencies

  • X-Linked Agammaglobulinemia (XLA): ((PHEM048)): BTK gene mutation causing defective B-cell maturation. Presents after 6 months of age with recurrent bacterial infections, absent tonsils and lymph nodes, and markedly reduced IgG, IgA, and IgM.
  • Chediak-Higashi Syndrome: ((PHEM049)): Autosomal recessive LYST gene mutation causing defective lysosomal trafficking. Features oculocutaneous albinism, silvery hair, recurrent pyogenic infections, and pathognomonic giant cytoplasmic granules in neutrophils.

Sickle Cell Disease & Complications

  • Osteomyelitis in Sickle Cell Disease: ((PHEM071)): Fever with localized bone pain, swelling, and warmth requires broad-spectrum IV antibiotics targeting Salmonella and Staphylococcus aureus, blood cultures, and aspiration. Do not delay antibiotics for imaging like MRI. Simple vaso-occlusive crises present without fever or local inflammation.
  • Stroke Prophylaxis via Transcranial Doppler (TCD): ((PHEM072)): Children with sickle cell disease and abnormal TCD velocities (>200 cm/s) carry a high stroke risk. The standard primary prophylaxis (supported by the STOP trial) is regular chronic transfusions targeting hemoglobin ~10 g/dL and HbS <30%.
  • Priapism in Sickle Cell Disease: ((((PHEM077)) · ((PHEM097)))): Erection lasting >4 hours is a low-flow (venous stasis) medical emergency. Initial acute management requires corporal aspiration followed by irrigation with dilute epinephrine. Exchange transfusion has limited initial utility and risks neurologic events.
  • Novel Sickle Cell Therapeutics: ((((PHEM098)) · ((PHEM099)))): - Crizanlizumab: Monthly IV P-selectin inhibitor reducing acute pain crises via cell adhesion blockade. - Casgevy (Exa-cel): Ex vivo autologous hematopoietic stem cell gene therapy utilizing CRISPR/Cas9 to disrupt BCL11A, elevating fetal hemoglobin (HbF). - Lyfgenia: Utilizes a lentiviral vector for $\beta^A$-T87Q globin gene addition.
  • Sickle Cell Trait & Athletic Participation: ((PHEM100)): Sickle cell trait is not an indication to exclude from competitive sports; allow participation with adequate oral hydration, frequent rest breaks, and heat exhaustion prevention.

Immune Thrombocytopenia (ITP) & Hemolytic Uremic Syndrome (HUS)

  • Chronic ITP Second-Line Therapy: ((PHEM073)): Children with chronic ITP refractory to first-line steroids/IVIG presenting with severe bleeding require rituximab (anti-CD20 monoclonal antibody) as first-choice second-line therapy. High-dose methylprednisolone offers only transient benefit.
  • Pediatric Acute ITP Management: ((PHEM074)): Abrupt-onset petechiae and isolated thrombocytopenia with minor bleeding in a hemodynamically stable child mandates close observation and reassurance (spontaneous recovery expected; platelet counts often >10,000–20,000/µL).
  • Hemolytic Uremic Syndrome (HUS): ((PHEM076)): Classic triad in a young child presenting with severe anemia, thrombocytopenia, and elevated reticulocytes: Microangiopathic hemolytic anemia (MAHA) with schistocytes, thrombocytopenia, and acute kidney injury. Triggered by E. coli O157:H7 Shiga toxin.

Red Cell Membrane, Enzymatic, & Congenital Dyserythropoietic Anemias

  • Hereditary Spherocytosis (HS): ((((PHEM075)) · ((PHEM091)) · ((PHEM092)))): - Characterized by hemolytic anemia, reticulocytosis, and spherocytes with MCHC >35.4 g/dL and RDW <14%. - Definitive management for severe disease is splenectomy, but it should ideally be delayed until after 6 years of age to mitigate post-splenectomy sepsis risks.
  • Rasburicase-Induced Hemolysis in G6PD Deficiency: ((PHEM077)): Rasburicase (urate oxidase) is contraindicated in G6PD deficiency; its metabolism generates hydrogen peroxide, precipitating acute hemolytic crisis, pallor, and congestive heart failure.
  • Congenital Dyserythropoietic Anemia Type II (CDA II): ((PHEM083)): Autosomal recessive disorder caused by biallelic variants in SEC23B. Mimics hereditary spherocytosis with anemia, jaundice, and splenomegaly, but distinguished by an inappropriately low reticulocyte count, binucleated/multinucleated erythroblasts with equal-sized nuclei, and hypoglycosylated band 3 with faster migration on SDS-PAGE.
  • X-Linked Dyserythropoietic Anemia: ((PHEM084)): Caused by pathogenic variants in GATA1, presenting with macrothrombocytopenia, poorly granulated platelets, bleeding manifestations, and marrow dyserythropoiesis.
  • Pyruvate Kinase Deficiency: ((PHEM105)): Chronic nonspherocytic hemolytic anemia with high reticulocytosis, normal hemoglobin electrophoresis, and polychromatophilia/pyknocytes. Confirmed via red cell pyruvate kinase activity assay.

Bone Marrow Failure Syndromes & PNH

  • Diamond-Blackfan Anemia (DBA): ((((PHEM080)) · ((PHEM081)))): - Early-onset macrocytic anemia with reticulocytopenia and marrow erythroid precursor paucity. - Associated with thumb/radial anomalies (triphalangeal thumb, duplex/bifid thumb, hypoplastic thumb, absent radial artery). Absent radius points to alternate radial ray disorders. - Oral L-leucine improves erythroid response, weight, and linear growth velocity.
  • Pure Red Cell Aplasia from ESAs: ((PHEM082)): Worsening severe anemia with marked reticulocytopenia despite adequate iron stores during erythropoiesis-stimulating agent (ESA) therapy indicates anti-EPO antibody-mediated pure red cell aplasia. Management requires stopping ESA therapy and initiating immunomodulatory therapy.
  • Paroxysmal Nocturnal Hemoglobinuria (PNH) & Marrow Failure: ((((PHEM094)) · ((PHEM095)) · ((PHEM096)))): - Subclinical PNH features a tiny GPI-anchor protein-deficient clone within aplastic anemia without intravascular hemolysis; manage the underlying bone marrow failure rather than giving eculizumab. - Testing is mandatory in Coombs-negative hemolysis with elevated LDH via flow cytometry (checking CD55/CD59).

Megaloblastic & Nutrition-Related Anemias

  • Hereditary Folate Malabsorption: ((PHEM086)): Caused by loss-of-function variants in SLC46A1 (proton-coupled folate transporter) presenting at 2–6 months with diarrhea, infections, seizures, developmental delay, and megaloblastic anemia with very low serum and CSF folate levels alongside loss of the normal CSF-to-serum folate gradient.
  • Imerslund-Gräsbeck Syndrome: ((PHEM087)): Megaloblastic anemia from vitamin B12 deficiency (due to CUBN or AMN mutations in the cubam receptor) accompanied by persistent proteinuria that does not correct with parenteral vitamin B12.
  • Hereditary Orotic Aciduria: ((PHEM088)): Infantile growth failure, developmental delay, and severe megaloblastic anemia unresponsive to vitamin B12/folate, caused by a de novo pyrimidine synthesis defect. Responds promptly to uridine.
  • Thiamine-Responsive Megaloblastic Anemia (Rogers Syndrome): ((PHEM088)): Caused by SLC19A2 variants, characterized by the triad of megaloblastic anemia, diabetes mellitus, and sensorineural deafness.

Hemoglobinopathies & Iron Overload

  • Hereditary Persistence of Fetal Hemoglobin (HPFH): ((PHEM078)): Markedly elevated HbF (~30%) with normal hemoglobin, normal MCV, normal reticulocyte count, and no clinical disease or anemia.
  • Hemoglobin D-Punjab: ((PHEM0101)): Heterozygous state is clinically silent, but co-inheritance with HbS produces a sickle cell disease phenotype.
  • Transfusional Iron Overload & Chelation: ((((PHEM102)) · ((PHEM103)))): - Deferiprone: Oral chelator uniquely associated with neutropenia and agranulocytosis requiring routine blood counts. - Luspatercept: Subcutaneous fusion protein given every 3 weeks for transfusion-dependent $\beta$-thalassemia; improves erythroid maturation via TGF-$\beta$ ligand trapping. Associated with bone pain and arthralgia. - Betibeglogene Autotemcel: One-time gene therapy using a lentiviral vector carrying a modified $\beta$-globin gene in harvested CD34+ cells.

Immune Hemolytic Anemia & Transfusion Medicine

  • Drug-Induced Immune Hemolytic Anemia Mechanisms: ((PHEM106)): Methyldopa classically induces true warm autoantibodies against RBCs. In contrast, penicillin acts via hapten/drug adsorption, and quinidine/quinine act via ternary immune-complex mechanisms.
  • Warm Autoimmune Hemolytic Anemia (WAIHA): ((PHEM107)): In refractory/chronic WAIHA unresponsive to glucocorticoids and IVIG, rituximab is the second-line monoclonal antibody used to target B lymphocytes and reduce autoantibody synthesis.
  • Cold Agglutinin Disease: ((PHEM108)): Caused by cold-reactive IgM antibodies. Direct Antiglobulin Test (DAT) is positive for C3 only (IgM is washed off). Poor reactivity with cord blood RBCs indicates anti-I specificity, classically triggered by Mycoplasma pneumoniae (whereas EBV typically associates with anti-i, showing strong reactivity with cord cells).
  • Pneumococcal-Induced Hemolytic Uremic Syndrome (HUS): ((PHEM109)): Streptococcus pneumoniae neuraminidase cleaves and exposes the T antigen on RBC and renal cell membranes. Plasma infusion must be strictly avoided because normal plasma contains natural anti-T antibodies that dangerously worsen hemolysis.
  • Neonatal & Pediatric Transfusion Protocols: ((((PHEM119)) · ((PHEM120)) · ((PHEM121)))): - For small-volume neonatal transfusions, a single RBC unit can be reserved and sampled for multiple aliquots throughout its storage life (up to 42 days). Fresh RBCs do not reduce major morbidities (NEC, ROP, BPD, IVH). - Leukoreduced CMV-untested platelets can be transfused immediately if CMV-seronegative units are unavailable; transfusion must not be delayed. - Blood products from blood relatives (partially HLA-matched) carry a high risk of transfusion-associated graft-versus-host disease and must always be irradiated prior to use.

Bone Marrow Failure Syndromes & Myelodysplasia

  • Polycythemia Vera: ((((PHEM110)) · ((PHEM111)))): Characterized by persistent erythrocytosis, low serum erythropoietin, trilineage marrow hypercellularity, and the JAK2 mutation. First-line management for hyperviscosity consists of phlebotomy combined with low-dose aspirin.
  • Fanconi Anemia: ((((PHEM112)) · ((PDPHEM113)))): - Carries an exceptionally high relative risk (~2,000-fold) for squamous cell carcinoma of the upper esophagus. - Diagnosed via chromosomal breakage studies using DEB or MMC. If peripheral lymphocyte testing is negative due to somatic mosaicism, testing must be repeated on cultured skin fibroblasts.
  • Shwachman-Diamond Syndrome: ((PHEM114)): Defined by bone marrow dysfunction, exocrine pancreatic insufficiency, and growth failure. Metaphyseal dysplasia may be absent initially. Definitive diagnosis requires genetic testing for SBDS, DNAJC21, and EFL1.
  • Hoyeraal-Hreidarsson Syndrome: ((PHEM115)): A severe infantile variant of dyskeratosis congenita featuring bone marrow failure, IUGR, reticulated skin pigmentation, oral leukoplakia, abnormal nails, and pathognomonic cerebellar hypoplasia (linked to DKC1 mutations).
  • Congenital Amegakaryocytic Thrombocytopenia (CAMT): ((PHEM116)): Caused by nonsense pathogenic variants in MPL (thrombopoietin receptor). Complete loss of receptor function leads to early severe thrombocytopenia and inevitable progression to pancytopenia and aplastic anemia.
  • Severe Acquired Aplastic Anemia: ((PHEM117)): For pediatric patients lacking an HLA-matched family donor, the primary treatment regimen is immunosuppressive therapy with horse antithymocyte globulin (ATG) and cyclosporine.
  • Pediatric Myelodysplastic Syndrome (MDS): ((PHEM118)): MDS with excess blasts is defined by peripheral blasts of 2–19% and/or marrow blasts of 5–19%. Monosomy 7 is the most frequent clonal cytogenetic anomaly. (Refractory cytopenia of childhood requires marrow blasts <5%).

Coagulation & Bleeding Disorders

  • Hemophilia A Dosing & Non-Factor Therapy: ((((PHEM122)) · ((PHEM123)))): - Emergency target factor VIII activity of 100% (e.g., for intracranial hemorrhage) is calculated via: `Desired rise (%) x weight (kg) x 0.5`.
  • *Emicizumab: * is a subcutaneous bispecific monoclonal antibody for prophylaxis that bridges activated factor IX and factor X, markedly shortening aPTT.
  • Rare Coagulation Factor Deficiencies: ((PHEM124)): Severe Factor X deficiency is an autosomal recessive disorder of the common pathway presenting in neonates with umbilical stump bleeding, intracranial hemorrhage, and prolongation of both PT and aPTT.
  • Von Willebrand Disease (VWD) Variants: ([PHEM125, Dimitrov/VWD126, PHEM127]):
  • Type 2N VWD: : Caused by defective VWF binding to factor VIII, leading to isolated low factor VIII activity that mimics mild hemophilia A (while VWF antigen, activity, and multimers are normal).
  • Type 2B VWD: : Gain-of-function variants increase VWF binding to platelet GPIb, causing enhanced clearance, thrombocytopenia, and hyper-responsiveness to low-dose ristocetin. Desmopressin is contraindicated as it exacerbates thrombocytopenia.
  • Antifibrinolytics: (e.g., tranexamic acid) are universally effective adjunctive treatments for mucosal bleeding across all VWD types.
  • Neonatal Purpura Fulminans: ((PHEM128)): Caused by homozygous protein C or protein S deficiency, presenting with rapidly spreading purpura, dermal vessel thrombosis, and DIC. Requires immediate empiric fresh frozen plasma infusion.

Thrombosis & Anticoagulant Management

  • Thrombolytic Therapy Monitoring: ((PHEM129)): When using recombinant tissue plasminogen activator for critical thrombosis, monitoring targets the induction of a "lytic state" via fibrin degradation products and D-dimer (unlike heparin which utilizes aPTT).
  • Direct Oral Anticoagulants (DOACs): ((PHEM130)): Dabigatran is a direct thrombin inhibitor with the highest renal elimination (>80%) among DOACs, requiring extreme caution in chronic kidney disease. Its specific reversal agent is idarucizumab.
  • VTE Treatment Duration: ((PHEM131)): A first-episode lower-limb VTE with a temporary, fully resolved provoking risk factor requires 3 months of therapeutic anticoagulation.

Platelet, Lymphatic & Vascular Anomalies

  • Inherited Platelet Disorders: ((((PHEM132)) · ((PHEM133)) · ((PHEM134)))):
  • Gray Platelet Syndrome: : Characterized by macrothrombocytopenia, absence of platelet $\alpha$-granules (gray appearance on smear), and progressive splenomegaly or marrow fibrosis.
  • IVIG-Induced Aseptic Meningitis: : A common complication following rapid ITP treatment presenting with severe headache, vomiting, and neck stiffness within 48 hours.
  • MYH9-Related Disorders: : Includes May-Hegglin anomaly, Epstein syndrome, and Fechtner syndrome, featuring macrothrombocytopenia, leukocyte inclusion bodies, and sensorineural deafness. (Paris-Trousseau/Jacobsen syndrome is distinct, caused by chromosome 11q deletion).
  • Splenectomy in Hereditary Spherocytosis: ((PHEM135)): Elective splenectomy should be postponed until the child is at least 5 years old to minimize the lifetime risk of overwhelming postsplenectomy infection from encapsulated bacteria.
  • Congenital Lymphatic & Vascular Malformations: ((((PHEM136)) · ((PHEM137)) · ((PHEM140)))): - Localized macrocystic lymphatic malformations: Treated primarily via interventional radiology-guided sclerotherapy (OK432, ethanol, bleomycin).
  • Milroy disease: : Primary congenital lymphedema caused by autosomal dominant mutations in VEGFR3.
  • Gorham-Stout disease: : A complex lymphatic anomaly distinguished by progressive cortical bone loss alongside chylous effusions.

Platelet Disorders & Congenital Marrow Failures

  • Glanzmann Thrombasthenia: ((PHEM141)): Defect/deficiency of platelet GPIIb/IIIa (integrin $\alpha$IIb$\beta$3) receptor. Hallmark is absent platelet aggregation with all physiological agonists (ADP, collagen, epinephrine, arachidonic acid) with normal aggregation to ristocetin. Platelet count and morphology are normal. (Distractor pearls: Bernard-Soulier syndrome features GPIb-IX-V deficiency, macrothrombocytopenia/giant platelets, and absent ristocetin aggregation).
  • Aplastic Anemia: ((PHEM143)): Characterized by severe pancytopenia with a markedly hypocellular bone marrow (<25% cellularity) replaced by fat and stromal elements. (Distractor pearls: ALL shows hypercellular marrow with lymphoblasts; MDS shows dysplastic cellular marrow; Megaloblastic anemia shows hypercellular marrow with megaloblasts).
  • Fanconi Anemia: ((((PHEM156)) · ((PHEM161)))): Inherited bone marrow failure syndrome presenting with pancytopenia, short stature, patchy hyperpigmentation, microcephaly, microphthalmia, café-au-lait spots, and characteristic bilateral absent thumbs or radial ray defects. (Distractor pearls: Diamond-Blackfan anemia features thenar eminence hypoplasia with a triphalangeal thumb, cleft lip/palate, and a shield chest with widely spaced nipples, without the pan-myeloid cytopenias early on).
  • Dyskeratosis Congenita: ((((PHEM155)) · ((CBT157)))): Telomere biology disorder presenting with progressive bone marrow failure, reticulate skin pigmentation, and progressive dystrophic nail changes. Characteristically associated with systemic complications including pulmonary fibrosis (reduced diffusion capacity), oral leukoplakia, and blocked lacrimal glands.

Red Blood Cell Morphology & Anemia Diagnostics

  • Iron Deficiency Anemia: ((((PHEM144)) · ((PHEM162)) · ((PHEM173)))): Peripheral smear shows microcytic hypochromic RBCs with pencil cells and poikilocytes. Hypochromia is defined by central pallor involving >1/3 of the red cell diameter. Clinical stigmata include smooth tongue, angular stomatitis, spoon-shaped nails (koilonychia), and blue sclera. Dietary note: Iron in breast milk has higher bioavailability than cow milk, protecting breastfed infants despite lower absolute iron content.
  • Megaloblastic Anemia: ((((PHEM145)) · ((PHEM158)))): Caused by Vitamin B12 or Folate deficiency. Smear shows macro-ovalocytes and hypersegmented neutrophils. Vitamin B12 deficiency specifically presents with posterior column signs (impaired vibration/position sense) and is clinically distinguished by the presence of vitiligo.
  • Howell-Jolly Bodies & Asplenia: ((PHEM146)): Howell-Jolly bodies are intraerythrocytic nuclear remnants normally cleared by the spleen; their presence indicates functional hyposplenism or asplenia, classically seen in sickle cell disease (predisposing to encapsulated organism sepsis).
  • Basophilic Stippling: ((PHEM147)): Punctate ribosomal RNA aggregates classically seen in lead toxicity, thalassemia, and myelodysplasia. (Distractor pearl: Sideroblastic anemia features marrow ring sideroblasts, not basophilic stippling).
  • Macrocytosis Differential: ((PHEM148)): Recognized causes include B12/folate deficiency, Diamond-Blackfan, Fanconi, aplastic anemia, liver disease, Down syndrome, hypothyroidism, and newborns. Kidney disease does not cause macrocytosis; it produces a normocytic anemia from reduced erythropoietin.
  • Pearson Syndrome: ((PHEM149)): Mitochondrial disorder mimicking Diamond-Blackfan anemia with early infantile macrocytic anemia and reticulocytopenia, but differentiated by multisystem disease (failure to thrive, exocrine pancreatic dysfunction), vacuolated marrow precursors, ringed sideroblasts, and heteroplasmic mitochondrial DNA deletions.
  • Congenital Sideroblastic Anemia: ((PHEM150)): Nonsyndromic X-linked forms caused by ALAS2 mutations; bone marrow iron stain reveals ring sideroblasts. A subset of patients responds to pyridoxine (Vitamin B6).
  • Hereditary Hydrocytosis: ((PHEM151)): Dominant erythrocyte volume regulation disorder with swollen stomatocytes, macrocytosis, low MCHC, increased red cell Na+/water, and decreased osmotic fragility. Splenectomy is contraindicated due to high risk of major postsplenectomy thrombosis.
  • Acanthocytosis Syndromes: ((PHEM152)): Red cells with irregular pointed projections (spur cells) associated with neuroacanthocytosis disorders like pantothenate kinase-associated neurodegeneration, chorea-acanthocytosis, and McLeod syndrome.
  • Sickle Cell Dactylitis (Hand-Foot Syndrome): ((PHEM153)): Symmetric/asymmetric painful swelling of hands/feet; often the very first clinical manifestation of sickle cell anemia in infancy (appearing by 2 years of age). Resolves with conservative pain management (differentiating from osteomyelitis).
  • G6PD Deficiency: ((PHEM154)): Oxidant hemolysis triggers bite cells. Never rule out G6PD deficiency based on a normal/low-normal enzyme level during an acute hemolytic crisis, because destruction of older cells leaves a reticulocyte-rich population with falsely normal enzyme levels; repeat testing after a few weeks.

General Anemia Physiology & Clinical Evaluation

  • Clinical Assessment & Thresholds: ((((PHEM159)) · ((PHEM160)) · ((PHEM164)) · ((PHEM165)) · ((PHEM166)))): - Reliable pallor sites: Tongue, nail beds, conjunctiva, palms, palmar creases (buccal mucosa is unreliable). - WHO anemia cutoff for children aged 5–11 years is <11.5 g/dL. - Slowly progressive anemia allows physiological compensation; symptoms attributable solely to anemia typically do not appear until Hb drops <7–8 g/dL. Severe anemia (<6 g/dL) causes a high-output state with ECG showing normal QRS complexes with ST-segment depression and T-wave flattening/inversion.
  • Corrected Reticulocyte Count Calculation: ((PHEM171)): $$\text{Corrected Reticulocyte Count (\%)} = \text{Reticulocyte Count (\%)} \times \frac{\text{Patient's Hb}}{\text{Normal Hb}}$$ A corrected count >2–3% indicates an appropriate/increased marrow response (hemolysis or hemorrhage), while a low count indicates hypoproliferation.
  • Anemia Workup & Management Pearls: ((((PHEM167)) · ((PHEM169)) · ((PHEM170)) · ((PHEM174)) · ((PHEM175)))): - Microcytic anemia with low serum iron, normal/high ferritin, and normal/low TIBC in the absence of blood loss requires checking ESR and CRP to rule out anemia of chronic disease / inflammation. - Normocytic anemia with low reticulocyte count and normal serum iron/systemic screens warrants a bone marrow biopsy to evaluate for aplastic anemia, pure red cell aplasia, or congenital dyserythropoietic anemia. - Oral iron failure: Failure to achieve expected Hb rise despite proven compliance mandates switching to IV iron. Total cumulative iron deficit must be calculated, and to minimize adverse reactions, the maximum single IV iron dose should not exceed 300 mg (or 7 mg/kg, whichever is lower), administered every 3–7 days.

Hematology & Transfusion Medicine

  • Iron Deficiency Anemia Management & Kinetics: ((PHEM176)): Earliest hematologic response to oral elemental iron is a reticulocyte response in 72–96 hours. Do not stop iron upon normalization of hemoglobin; continue oral iron for 4–6 months after correction of anemia to replenish depleted body iron stores.
  • Deferoxamine Therapy Buzzwords: ((PHEM177)): Deferoxamine (DFO) chelates ferric iron to form the ferrioxamine complex, leading to a benign orange or reddish-orange urinary discoloration that does not indicate renal toxicity, over-chelation, or require dose reduction.
  • Disabilities Recognized under RPWD Act (2016): ((PHEM178)): The Rights of Persons with Disabilities (RPWD) Act, 2016 officially recognizes thalassemia, hemophilia, and sickle cell disease as specified disabilities eligible for welfare benefits (severe aplastic anemia, hereditary spherocytosis/elliptocytosis are not included).
  • Osteomyelitis vs Vaso-Occlusive Crisis in Sickle Cell: ((PHEM179)): When a patient with sickle cell disease presents with bone pain failing to improve after 72 hours and MRI shows marrow edema, osteomyelitis must be suspected. Do not wait for blood cultures; initiate empirical intravenous antibiotics and obtain image-guided bone aspiration/biopsy for definitive microbiology.
  • Acute Chest Syndrome (ACS) Trigger Threshold: ((PHEM180)): In acute chest syndrome (ACS), start supplemental oxygen immediately if oxygen saturation falls by ≥4% from baseline or drops below 90% (even if absolute saturation is still >90%).
  • Endocrine Surveillance in Thalassemia Major: ((PHEM181)): Due to transfusional hemosiderosis, routine endocrine surveillance (monitoring growth, thyroid, glucose, parathyroid, and pubertal status) must begin at approximately 5 years of age or after at least 3 years of chronic transfusions, whichever is later. Do not wait for symptoms or growth delays to manifest.
  • Neonatal Transfusion: CMV & Irradiation Guidelines: ((PHEM182)): For very-low-birth-weight neonates (<1,500 g), use irradiated, prestorage leukoreduced RBCs. Do not delay transfusion for CMV-seronegative blood; CMV-untested leukoreduced units can be safely transfused immediately as prestorage leukoreduction has extremely low residual CMV transmission risk.
  • Prophylactic Platelet Transfusion Threshold: ((PHEM183)): In clinically stable children with chemotherapy-induced marrow failure lacking active bleeding or invasive procedures, maintain a prophylactic platelet count threshold of >10 × 10⁹/L.
  • Neonatal Megakaryocyte Response to Thrombocytopenia: ((PHEM184)): Unlike older children/adults (who respond via increased megakaryocyte size and ploidy first), neonates respond to high platelet demand predominantly by increasing megakaryocyte number while showing minimal increase in size or ploidy, yielding numerous small, cytoplasmically mature megakaryocytes with limited output.
  • Granulocyte Transfusion Donor Criteria: ((PHEM185)): Granulocyte transfusions for refractory febrile neutropenia require an ABO/Rh-compatible donor (due to high RBC contamination) who is CMV-seronegative and screened recently for HIV/hepatitis.
  • Plasma Products: FFP vs. F24: ((PHEM186)): Plasma frozen within 24 hours (F24) contains slightly lower levels of factors V and VIII (≤25% lower) compared to fresh-frozen plasma (FFP) (frozen within 8 hours), but it is clinically interchangeable with FFP for routine pediatric plasma transfusion indications.